The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.
 
Jonathan Alexander Chatzkel
No Relationships to Disclose
 
Jennifer Swank
No Relationships to Disclose
 
Steven Ludlow
No Relationships to Disclose
 
Kristina Lombardi
No Relationships to Disclose
 
Cortlin Croft
No Relationships to Disclose
 
Yesenia Artigas
No Relationships to Disclose
 
Yazmin Rodriguez
No Relationships to Disclose
 
Tina Terraciano
No Relationships to Disclose
 
Sarah Hart
No Relationships to Disclose
 
Jennifer Rembisz
No Relationships to Disclose
 
Elaine Johnson
No Relationships to Disclose
 
Michael J. Schell
No Relationships to Disclose
 
Jiqiang Yao
No Relationships to Disclose
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Sanofi
Speakers' Bureau - AstraZeneca/MedImmune; Sanofi
Research Funding - Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst)
 
Mayer N. Fishman
Consulting or Advisory Role - Novartis; Pfizer; Pfizer
Speakers' Bureau - Exelixis; Ipsen; Medivation
Research Funding - Acceleron Pharma (Inst); Alkermes (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Prometheus (Inst)